On the afternoon of March 26, the 2026 Intelligent Health Technology Conference—centered on “Interdisciplinary Innovation and Collaboration between Medicine and Engineering”—concluded successfully in the World Expo Puxi Science and Innovation Zone in Shanghai’s Huangpu District. Organized jointly by the Shanghai Association for Artificial Intelligence Technology and the Huangpu Central Science & Innovation Zone Construction Working Group Office, with technical guidance from the United Nations Industrial Development Organization (UNIDO) Investment and Technology Promotion Office (ITPO China–Shanghai), the event brought together policymakers, clinicians, academic researchers, and technology innovators to chart a course for industry-academia-clinical integration in the era of Intelligent Health 3.0.
At the conference, Lou Wei, President of the Shanghai Association for Artificial Intelligence Technology, underscored that true translational impact hinges on closing the innovation loop: “Research and development must move beyond the lab, into clinical practice, and ultimately into sustainable commercialization—only then can we unlock the compounding benefits of health technology transfer.” Chen Yongliang, Executive Deputy Director of the Huangpu Central Science & Innovation Zone Construction Office, highlighted the district’s strategic advantage: world-class clinical infrastructure—including top-tier hospitals and translational medicine platforms—combined with dedicated support services to foster high-impact international technology transfer and scalable health tech entrepreneurship.
A major milestone was announced during the event: the official launch of the Association’s “Medical-Engineering Interdisciplinary Technology and Industrial Innovation Center” within the World Expo Puxi Zone. Simultaneously, the “Life Renewal Harbor”—a dedicated intelligent health technology industrial cluster—was inaugurated. Representatives from leading universities, tertiary hospitals, technology enterprises, and global business partners joined the ribbon-cutting, signaling the operational readiness of a fully integrated ecosystem spanning discovery, validation, regulatory approval, clinical deployment, and market adoption.
Among the featured innovators was Keeploop Shengshengji (Shengshengji Biotech), which unveiled its next-generation cardiovascular monitoring platform aligned with the principles of Intelligent Health 3.0. Liu Rongyun, Vice President of the Shanghai AI Association and Founder & CEO of Shengshengji, articulated a paradigm shift: “Over the next decade, the most consequential advances in health management won’t occur inside hospitals—but in people’s daily lives. Hospitals determine whether disease is treatable; everyday health behaviors determine quality of life and longevity.” He described this evolution as a transition from reactive care to proactive sensing—and from episodic diagnostics to continuous, context-aware physiological insight.
This shift is especially urgent in cardiovascular disease prevention. In China, over 330 million individuals live with pan-vascular disorders, and cardiovascular disease claims approximately 4.58 million lives annually. Conventional electrocardiographic (ECG) monitoring faces critical limitations: standard resting ECGs capture only seconds of cardiac activity—missing intermittent arrhythmias—while traditional Holter monitors impose significant burdens: cumbersome electrode wiring, inability to shower or exercise normally, and long wait times for device allocation and interpretation.
To address these gaps, Shengshengji introduced “AI Heart Explorer,” a medical-grade wearable ECG monitor cleared for clinical use. The device enables seamless 24- to 72-hour continuous ambulatory monitoring without compromising daily activities. Its lightweight, adhesive-free design ensures comfort and compliance, while clinical validation confirms a 99.6% detection rate for clinically relevant arrhythmias—including atrial fibrillation, premature ventricular contractions, and brady-tachy syndromes—at diagnostic accuracy meeting Class II medical device standards. Critically, “AI Heart Explorer” integrates directly with Fudan University Shanghai Medical College Affiliated Zhongshan Hospital: raw data is transmitted securely to the hospital’s cloud-based analysis platform, where cardiologists generate formal diagnostic reports—enabling users to complete full-cycle cardiac assessment from home, without an in-person clinic visit.
“Historically, patients traveled to hospitals for testing. Today, high-fidelity diagnostics travel into patients’ homes,” said Liu. “Our mission is to bring China’s gold-standard cardiology evaluation into tens of millions of households.” Complementing “AI Heart Explorer,” Shengshengji also demonstrated two synergistic technologies: “AI NeuroExplorer,” an AI-powered analytical engine leveraging neural signal modeling and computational neuroscience to derive predictive biomarkers from multi-modal physiological data; and the “Jinguang Ionizer,” a non-invasive physical intervention device applying plasma ionization technology—originally developed in national key laboratories—for targeted modulation of autonomic nervous system function. Together, these three components form a closed-loop Intelligent Health 3.0 architecture: real-time *perception*, AI-driven *insight*, and evidence-based *intervention*.
“AI Heart Explorer” is now commercially available via online channels. Experts at the conference emphasized that successful medical-engineering convergence demands more than technical excellence—it requires fluent communication across disciplines and unwavering commitment to human-centered design. Only when cutting-edge science becomes intuitive, accessible, and actionable can health technology fulfill its promise: transforming passive illness management into active, personalized health stewardship—and empowering every individual with agency over their own well-being.
Building on its base in Huangpu District, Shengshengji aims to accelerate global adoption of its intelligent health platform—advancing not just Chinese innovation, but globally resonant solutions for preventive cardiology and lifelong wellness.